| Literature DB >> 22533972 |
Ian C Nicholson1, Christos Mavrangelos, Daniel R G Bird, Suzanne Bresatz-Atkins, Nicola G Eastaff-Leung, Randall H Grose, Batjargal Gundsambuu, Danika Hill, Debbrah J Millard, Timothy J Sadlon, Sarah To, Heddy Zola, Simon C Barry, Doreen Krumbiegel.
Abstract
The peptidase inhibitor PI16 was shown previously by microarray analysis to be over-expressed by CD4-positive/CD25-positive Treg compared with CD4-positive/CD25-negative Th cells. Using a monoclonal antibody to the human PI16 protein, we found that PI16-positive Treg have a memory (CD45RO-positive) phenotype and express higher levels of FOXP3 than PI16-negative Treg. PI16-positive Treg are functional in suppressor assays in vitro with potency similar to PI16-negative Treg. Further phenotyping of the PI16-positive Treg revealed that the chemokine receptors CCR4 and CCR6 are expressed by more of the PI16-positive/CD45RO-positive Treg compared with PI16-negative/CD45RO-positive Treg or Th cells. PI16-positive Treg showed enhanced in vitro migration towards the inflammatory chemokines CCL17 and CCL20, suggesting they can migrate to sites of inflammation. We conclude that PI16 identifies a novel distinct subset of functional memory Treg which can migrate to sites of inflammation and regulate the pro-inflammatory response at those sites.Entities:
Mesh：
Substances：
Year: 2012 PMID： 22533972 DOI： 10.1016/j.cellimm.2012.04.002
Source DB: PubMed Journal: Cell Immunol ISSN： 0008-8749 Impact factor: 4.868